Congratulations to the research team at the RD&E who have worked really hard to get the first patient recruited to the GILEAD Alpine Study.  The primary objective of this study is to evaluate the safety and efficacy of a 14-day course versus a 28-day course of aztreonam for inhalation solution (AZLI) in participants with new onset Pseudomonas aeruginosa respiratory tract infection.